arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

PharmaCyte Biotech, Inc.

PMCB
$0.36 ▼ -0.03 (-6.83%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
65 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

PharmaCyte Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.9M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -2.9% ↗
FCF / Share $-0.07
Trailing P/E —
Price / Book 0.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-5.08M
↑ +39.2% —
FCF / Share Free cash flow per share
$-0.07
↑ +75.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
13
Cash Quality ↓
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 65 quarters